



Maryland Department of Health and Mental Hygiene 201 W. Preston Street • Baltimore, Maryland 21201 Parris N. Glendening, Governor - Georges C. Benjamin, M.D., Secretary

MARYLAND MEDICAL ASSISTANCE PROGRAM Pharmacy Transmittal No. 163 Managed Care Organization Transmittal No. 21 November 3, 2000

- TO: Managed Care Organizations Physicians Pharmacists
- FROM: Joseph M. Millstone, Executive Director MM Office of Health Services
- **NOTE:** Please ensure that appropriate staff members in your organization are informed of the contents of this transmittal.
- RE: Changes to Mental Health and AIDS Carve-Out Drugs for Recipients in Managed Care Organizations

This transmittal is to inform you about changes that the MCOs must make to their pharmacy formularies.

Effective January 1, 2001 amendments to managed care regulations establish a new Specialty Mental Health System (SMHS) formulary (see attachment). These nine therapeutic classes of drugs listed in this formulary will be paid as fee-for-service by the Program with the exception of the six drugs marked with an asterisk, which are the responsibility of the MCOs.

Also, effective January 1, 2001, all MCOs will be required to include on their formularies the seven drugs listed below. These specific drugs are used in the treatment of a variety of illnesses including mental illness, and therefore, these drugs as well as the six drugs discussed earlier in this transmittal are the responsibility of the MCOs regardless of the prescriber. LeuprolideMedroxyprogesteroneClonidineLiothyronineGuanfacineDisulfiramNaltrexone

Two drugs, leuprolide and medroxyprogesterone, when used to treat behavioral problems, will be paid by the Program but will require preauthorization. These will be approved for males only.

Each MCO must instruct its Pharmacy Benefits Manager to include the required drugs on its formulary effective January 1, 2001. The Program will monitor the formularies of the managed care organizations for compliance to these requirements. Pharmacists should bill the appropriate payor based on the formulary, regardless of the prescriber.

These managed care regulation amendments also change coverage responsibility for certain drugs used to treat the AIDS virus. Protease inhibitors and non-nucleoside reverse transcriptase inhibitors, which were previously paid fee-for-service are now included in the managed care capitation rate and the MCOs will be responsible for payment of these prescriptions effective January 1, 2001. Coverage of any new drugs for the treatment approved by the FDA starting 2001 will also be the responsibility of MCOs.

Questions concerning this transmittal should be directed to the Pharmacy Section of the Division of Pharmacy and Clinic Services at 410-767-1455.

Attachments JG/DH/kag

A.

Y

Mental Health Formulary Carved-out of Managed Care and Payable as Fee-For-Service

The six drugs that have been bolded and marked with a "*" are exceptions to the carve out and must be covered by the MCOs. All drugs that are in these classes including those not listed in this table, are carved out and represent the mental health formulary.

Therapeutic Class	Drug
Class No. 120804	Benztropine
Antiparkinsonian Agents	Biperiden
	Procycildine
	Trihexyphenidyl
Class No. 281208	Clonazepam
Benzodiazepines	
Class No. 281292	Valproate/Divalproex
Miscellaneous Anticonvulsants	
	Carbamazepine*
	Gabapentin*
	Lamotrigine*
	Topiramate*
Class No. 281604	Phenelzine
Antidepressants	Tranylcypromine
F	Amitriptyline
	Amoxapine
	Clomipramine
	Desipramine
	Doxepin
	Imipramine
	Maprotiline
	Nortriptyline
	Protriptyline
	Trimipramine
	Bupropion
	Fluoxetine
	Fluvoxamine
	Sertraline
	Paroxetine
	Nefazodone
	Veniafaxine
	Mirtazapine
	Trazodone
	Citalopram
	All other agents in this class
Class No. 281608	Chlorpromazine
Antipsychotic Agents	Fluphenazine
	Mesoridazine
	Perphenazine
	Thloridazine
 Figure 1 (1) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2	Trifluoperazine
	Triflupromazine
	Haloperidol
	Thiothixene
	Chlorprothixene
	Pimozide

	Loxapine Molindone Clozapine Olanzapine Risperidone Quetiapine All other agents in this class with the exception of prochloroperazine and promazine
Class No. 282000 Anorexigenic Agents and Respiratory and Cerebral Stimulants	Amphetamine Dextroamphetamine Methamphetamine Methylphenidate Pemoline
Class No. 282408 Anxiolytics, Sedatives and Hypnotics – Benzodiazepines	Alprazolam Chlordiazepoxide Clorazepate Diazepam Estazolam Flurazepam Halazepam Lorazepam Midazolam* Oxazepam Quazepam Temazepam
Class No. 282492 Miscellaneous Anxiolytics, Sedatives and Hypnotics	Buspirone Chloral Hydrate Droparidol* Hydroxyzine Meprobamate Zolpidem
Class No. 282800 Antimanic Agents	Lithium

10.09.67 Maryland Medicaid Managed Care Program: Benefits

Authority: Health-General Article, Title 15, Subtitle 1, Annotated Code of Maryland

.04 Benefits—Pharmacy Services.

A. An MCO shall provide to its enrollees all medically necessary and appropriate pharmaceutical services and pharmaceutical counseling, including but not limited to:

(1) - (9) (text unchanged)

(10) Medical supplies or equipment used in the administration or monitoring of medication prescribed or ordered for an enrollee by a qualifying provider as specified in §B of this regulation; and

(11) Psychotropic drugs prescribed or ordered by the MCO's provider within the scope of the provider's license and for the treatment of primary mental health care services, unless the MCO also provides

specialty mental health care services pursuant to authority granted by the Department's regulations; and

(12) Latex condoms.

B. Except as provided in §C of this regulation, an MCO is required to provide only those drugs and related pharmaceutical products that are prescribed or ordered by:

(1) - (2) (text unchanged)

(3) A SMHS provider for drugs not in the SMHS formulary.

C. (text unchanged)

D. Drug Formulary.

(1) - (3) (text unchanged)

24

(4) An MCO shall include in its formulary the following drugs:

(a) Carbamazepine;

(b) Gabapentin;

(c) Lamotrigine;

(d) Topiramate;

(e) Midazolam;

(f) Droperidol;

(g) Leuprolide acetate;

(h) Clonidine;

(i) Guanfacine;

(j) Naltrexone;

(k) Medroxyprogesterone;

(1) Liothyronine; and

(m) Disulfiram.

[(4)] (5) (text unchanged)

E. - F. (text unchanged)

Dental Services.

A. An MCO shall provide medically necessary and tal services for i enrollees who are younger the including but not ______to:

(1) (text unchanged)

(2) For children who are at least 3

semiannual

old

ſ

Semiaanual cleaning, fluoride treatment, and

25

.....

.27 Benefits

A. (text unchanged)

B. The benefits or s not required to be provided under §A of this regulation are as

(1) - (26) (text unchanged)

(27) Payment for 1 ; categories of drugs used in the treatment of HIV/AIDS, the provision of which will be reimbursed directly by the Department:

- (a) Protease inhibitors; and
- (b) Non-nucleoside reverse transcriptase inhibitors;

[(28)] (27) - [(39)] (38) (text unchanged)

(39) Genotypic, phenotypic or other HIV/AIDS drug resistance testing used in the

treatment of HIV/AIDS, the provision of which will be reimbursed directly by the

Department if the service is:

(a) Rendered by a Department approved provider; and

(b) Medically necessary and appropriate.

(40) Except for those listed in Regulation .04D(4) of this chapter, drugs that are

included in the SMHS formulary.

